328 related articles for article (PubMed ID: 35456049)
21. The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma.
Li J; Shi C; Zhou R; Han Y; Xu S; Ma H; Zhang Z
Cancer Sci; 2020 Sep; 111(9):3222-3235. PubMed ID: 32589311
[TBL] [Abstract][Full Text] [Related]
22. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
[TBL] [Abstract][Full Text] [Related]
23. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell.
Plouffe SW; Lin KC; Moore JL; Tan FE; Ma S; Ye Z; Qiu Y; Ren B; Guan KL
J Biol Chem; 2018 Jul; 293(28):11230-11240. PubMed ID: 29802201
[TBL] [Abstract][Full Text] [Related]
24. A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma.
Hiemer SE; Zhang L; Kartha VK; Packer TS; Almershed M; Noonan V; Kukuruzinska M; Bais MV; Monti S; Varelas X
Mol Cancer Res; 2015 Jun; 13(6):957-68. PubMed ID: 25794680
[TBL] [Abstract][Full Text] [Related]
25. YAP and TAZ play a crucial role in human erythrocyte maturation and enucleation.
Damkham N; Lorthongpanich C; Klaihmon P; Lueangamornnara U; Kheolamai P; Trakarnsanga K; Issaragrisil S
Stem Cell Res Ther; 2022 Sep; 13(1):467. PubMed ID: 36076260
[TBL] [Abstract][Full Text] [Related]
26. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
27. Hippo signaling pathway in companion animal diseases, an under investigated signaling cascade.
Budel SJ; Penning MM; Penning LC
Vet Q; 2021 Dec; 41(1):172-180. PubMed ID: 33945400
[TBL] [Abstract][Full Text] [Related]
28. YAP signaling induces PIEZO1 to promote oral squamous cell carcinoma cell proliferation.
Hasegawa K; Fujii S; Matsumoto S; Tajiri Y; Kikuchi A; Kiyoshima T
J Pathol; 2021 Jan; 253(1):80-93. PubMed ID: 32985688
[TBL] [Abstract][Full Text] [Related]
29. YAP/TAZ: Drivers of Tumor Growth, Metastasis, and Resistance to Therapy.
Thompson BJ
Bioessays; 2020 May; 42(5):e1900162. PubMed ID: 32128850
[TBL] [Abstract][Full Text] [Related]
30. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
[TBL] [Abstract][Full Text] [Related]
31. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
Nishina H
Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
[TBL] [Abstract][Full Text] [Related]
32. The role of Hippo-YAP signaling in squamous cell carcinomas.
Maehama T; Nishio M; Otani J; Mak TW; Suzuki A
Cancer Sci; 2021 Jan; 112(1):51-60. PubMed ID: 33159406
[TBL] [Abstract][Full Text] [Related]
33. The transcriptional co-activator YAP: A new player in head and neck cancer.
Segrelles C; Paramio JM; Lorz C
Oral Oncol; 2018 Nov; 86():25-32. PubMed ID: 30409308
[TBL] [Abstract][Full Text] [Related]
34. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
35. DUB1 suppresses Hippo signaling by modulating TAZ protein expression in gastric cancer.
Wang D; Li Z; Li X; Yan C; Yang H; Zhuang T; Wang X; Zang Y; Liu Z; Wang T; Jiang R; Su P; Zhu J; Ding Y
J Exp Clin Cancer Res; 2022 Jul; 41(1):219. PubMed ID: 35820928
[TBL] [Abstract][Full Text] [Related]
36. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
Kim M; Kim T; Johnson RL; Lim DS
Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
[TBL] [Abstract][Full Text] [Related]
38. New insights into the ambivalent role of YAP/TAZ in human cancers.
Luo J; Deng L; Zou H; Guo Y; Tong T; Huang M; Ling G; Li P
J Exp Clin Cancer Res; 2023 May; 42(1):130. PubMed ID: 37211598
[TBL] [Abstract][Full Text] [Related]
39. TAZ and YAP are frequently activated oncoproteins in sarcomas.
Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
[TBL] [Abstract][Full Text] [Related]
40. [Research advances in the role of the Hippo-YAP/TAZ signaling pathway in primary liver cancer].
Guo LW; Shao GL
Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):878-880. PubMed ID: 29325286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]